Historically, AstraZeneca (LON:AZN) was a leading global pharmaceutical company, but it has slipped down the rankings following a period of patent expiry on major drugs, notably Nexium, Losec and Seroquel.
LightwaveRF (LON:LWRF) has announced strong results for the six-month period to end-March 2019. Revenue more than doubled, accompanied by an uplift in gross margin, reflecting the evolution of the company’s
Chamberlin Plc (LON:CMH), Prospects remain very uncertain, and cost reduction measures continue to be implemented. Chamberlin remains on track strategically. The group continues to develop its product offering to the
Morses Club Plc (LON:MCL) We took two key messages from the FY’19 results announced on 2 May. First, the core business is now in a reliable, steady state with modest
Urban Logistics (LON:SHED) results (24 May) were robust. Prospects for continuing value-adding investment and capital recycling are clear and strong. SHED owns “mid-box”, “last mile” distribution warehouses. Just as important
Titon Holdings Plc (LON:TON), Failure to applaud is the original meaning of the idiom ‘to sit on your hands’; it originated in the theatre, when an unimpressed audience refused to
Allergy Therapeutics (LON:AGY) is a long-established specialist in the prevention, diagnosis and treatment of allergies. The Pollinex Quattro (PQ) platform, an ultra-short-course subcutaneous allergy immunotherapy (SCIT), continues to gain market
Palace Capital (LON:PCA) portfolio and trading update of 2 May showed underlying values up year- on-year. A lease event, resulting in a profit and cash upgrade, was announced on 7
Artificial Solutions (NASDAQ:ASAI.SE) 1Q results for the three months ended March 2019 confirm that the company remains on track to meet its FY’19 expectations. A number of new customer wins have
At Hardman and Co, we try to answer the questions of why to invest in a company and what the risks are in doing so. For many investors, simply having
© 2024 – DirectorsTalk. All rights reserved. Reproduction in whole or in part, in any form or medium without express written permission is prohibited.
